ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesD02.2

D02.2

Billable

Carcinoma in situ of bronchus and lung

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/05/2025

Code Description

ICD-10 D02.2 is a billable code used to indicate a diagnosis of carcinoma in situ of bronchus and lung.

Key Diagnostic Point:

Carcinoma in situ of the bronchus and lung refers to a localized form of lung cancer where abnormal cells are present in the lining of the bronchus or lung but have not invaded deeper tissues or spread to other parts of the body. This condition is characterized by the presence of neoplastic cells that exhibit malignant characteristics but remain confined to the site of origin. Early detection is crucial, as carcinoma in situ can progress to invasive lung cancer if left untreated. Patients may be asymptomatic or present with nonspecific respiratory symptoms. Surveillance protocols typically involve regular imaging studies, such as chest X-rays or CT scans, and bronchoscopy for direct visualization and biopsy of suspicious lesions. The risk of progression to invasive carcinoma varies based on factors such as the size of the lesion, histological subtype, and patient risk factors, including smoking history and genetic predisposition. Management may include surgical resection, radiation therapy, or active surveillance, depending on the individual case.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Differentiating between in situ and invasive carcinoma
  • Need for precise documentation of tumor characteristics
  • Variability in clinical presentation and symptoms
  • Potential for co-existing lung conditions

Audit Risk Factors

  • Inadequate documentation of tumor staging
  • Failure to specify the site of carcinoma
  • Misclassification of in situ versus invasive carcinoma
  • Lack of follow-up documentation for surveillance

Specialty Focus

Medical Specialties

Oncology

Documentation Requirements

Detailed pathology reports, imaging studies, and treatment plans must be documented.

Common Clinical Scenarios

Patients diagnosed with carcinoma in situ undergoing surveillance or treatment.

Billing Considerations

Ensure accurate staging and grading of the tumor to guide treatment decisions.

Pulmonology

Documentation Requirements

Pulmonary function tests, imaging results, and clinical notes regarding respiratory symptoms.

Common Clinical Scenarios

Patients presenting with respiratory symptoms and requiring bronchoscopy for diagnosis.

Billing Considerations

Document any co-existing lung diseases that may affect treatment options.

Coding Guidelines

Inclusion Criteria

Use D02.2 When
  • Follow the official ICD
  • CM coding guidelines, ensuring accurate documentation of the diagnosis, including the site and characteristics of the carcinoma

Exclusion Criteria

Do NOT use D02.2 When
  • Exclude any conditions that do not meet the criteria for carcinoma in situ

Related ICD-10 Codes

Related CPT Codes

31622CPT Code

Bronchoscopy, rigid or flexible, including fluoroscopic guidance

Clinical Scenario

Used for diagnosis and biopsy of suspected carcinoma in situ.

Documentation Requirements

Document indications for bronchoscopy, findings, and any biopsies performed.

Specialty Considerations

Pulmonologists should ensure thorough documentation of the procedure and findings.

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving data accuracy and facilitating better tracking of treatment outcomes.

ICD-9 vs ICD-10

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving data accuracy and facilitating better tracking of treatment outcomes.

Reimbursement & Billing Impact

The transition to ICD-10 has allowed for more specific coding of carcinoma in situ, improving data accuracy and facilitating better tracking of treatment outcomes.

Resources

Clinical References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Coding & Billing References

  • •
    ICD-10-CM Official Guidelines for Coding and Reporting

Frequently Asked Questions

What is the difference between carcinoma in situ and invasive carcinoma?

Carcinoma in situ is a localized cancer that has not invaded surrounding tissues, while invasive carcinoma has spread beyond the original site, requiring different treatment approaches and coding.